Table 2.

Grade 3 to 5 adverse events in the JVBE study (incidence ≥ 3%)

Ramucirumab/PACPlacebo/PAC
Adverse event(n = 327)(n = 329)
Neutropenia133 (41%)62 (19%)
Leukopenia57 (17%)22 (7%)
Hypertension46 (14%)8 (2%)
Anemia30 (9%)34 (10%)
Fatigue/asthenia39 (12%)18 (5%)
Abdominal pain18 (6%)11 (3%)
Ascites12 (4%)13 (4%)
Diarrhea12 (4%)5 (2%)
Decreased appetite10 (3%)13 (4%)
Vomiting10 (3%)12 (4%)
General physical health deterioration11 (3%)11 (3%)
Dehydration9 (3%)8 (2%)
Febrile neutropenia10 (3%)8 (2%)
Peripheral neuropathy10 (3%)7 (2%)
Hyponatremia11(3%)4 (1%)
Pulmonary embolism4 (1%)10 (3%)

NOTE: Grade 5 events listed in this table were general physical health deterioration (2 in the placebo arm, 1 in ramucirumab arm), dehydration (1 in the ramucirumab arm), febrile neutropenia (1 in the placebo arm), and pulmonary embolism (2 in the placebo arm, 1 in the ramucirumab arm).

Abbreviation: PAC, paclitaxel.